Interferon Gamma Release Assay as Diagnosis Of Latent Mycobacterium tuberculosis Infection
DOI:
https://doi.org/10.53089/medula.v10i3.90Keywords:
IGRA, Laten infection, Mycobacterium tuberculosaAbstract
Mycobacterium tuberculosa (Mtb) infection is influenced by host-specific factors and pathogens interacting with the environment in a complex way to determine the outcome of infection. The result of infection with Mycobacterium tuberculosa is one of three possible outcomes, which are cured, latent, or active. asymptomatic latent tuberculosis infection, which is defined as a state of persistent bacterial viability, immune control, and no evi- dence of clinically manifested active tuberculosis. Latent tuberculosis infection (LTBI) is a persistent immunological evidence in the asymptomatic phase of active TB infection. LTBI can develop into active TB that depends on host factors, pathogens and the environment. The diagnosis of LTBI can reduce the rate of active TB by providing preventive therapy. At present one of the checks that can diagnose LTBI is the examination of Interferon Gamma Release Assay (IGRA) in addition to the tuberculin skin test (TST). The purpose of this study was to determine the specificity and sensitivity of the IGRA examination as a diagnosis of latent Mycobacterium tuberculosis infection. The result is IGRA examination is more specific and sensitive, unless active with TST that is unable to determine active TB or not
References
World Health Organization, Global Tuberculosis Control: WHO Report. World Health Organization, Geneva, Switzerland. 2011.
Esmail H, Iii CEB, Wilkinson RJ. Understanding latent tuberculosis : the key to improved diagnostic and novel treatment strategies. Drug Discov Today. Elsevier Ltd. 2012; 17(9–10): 514–21.
Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis Infection. N Engl J Med. 2015; 372(2): 2127–35.
Salgame P, Geadas C, Collins L, Jones-l E, Ellner JJ. Latent tuberculosis infection - Revisiting and revising concepts. Tuberculosis. 2015; (May): 1–11.
Pai M, Denkinger CM, Kik S V, Rangaka MX, Zwerling A, Oxlade O, Dkk. Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection. Clin Microbiol Rev. 2014.; 27(1): 3–20.
Sali M, Buonsenso D, Alfonso PD, Palucci I, Chiacchio T, Goletti D, Dkk. Combined use of Quantiferon and HBHA-based IGRA supports tuberculosis diagnosis and therapy management in children. J Infect. Elsevier Ltd. 2018; 1–20.
Smith R, Cattamanchi A, Steingart KR, Denkinger C, Dheda K, Winthrop KL, Dkk. Interferon-gamma release assays for diagnosis of latent tuberculosis infection : evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol. 2011; 23: 377–84.
Goletti D, Petruccioli E, Joosten SA, Ottenhoff THM. Tuberculosis biomarkers : from diagnosis to protection. Infect Dis Rep. 2016; 8(6568): 24–32.
Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, Dkk. Tuberculosis infection : a systematic review. Eur Respir J. 2011; 37(1):88–99.
Herrera V, Perry S, Parsonnet J, Banaei N. Clinical Application and Limitations of Interferon- g Release Assays for the Diagnosis of Latent Tuberculosis Infection. Clin Pract. 2011; 52: 1031–7.
Trajman A, Steffen RE, Menzies D. Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection : An Overview of the Evidence. Pulm Med. 2013: 1-11.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 MEDULA
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
